Replies to post #468634 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

Pazzo1212, Thank you for posting the CTAD agenda.

Pre-specified SIGMAR1 Gene Variant Analysis in Phase IIb/III Trial Supports Precision Medicine Mechanism of Action (MoA) with Improved Treatment Effect of Blarcamesine in Early Alzheimer Disease
Marwan N. Sabbagh 1, Juan Carlos Lopez-Talavera 2, Kun Jin 2, William Robert Chezem 2, Christopher U. Missling 2
1Barrow Neurological Institute - Phoenix (United States), 2Anavex Life Sciences - New York (United States)

Good luck and GOD bless,

[Steady_T]

Thanks for bringing that to the board.

A little more awareness of the company amongst the professionals.

Pre-specified SIGMAR1 Gene Variant Analysis in Phase IIb/III Trial Supports Precision Medicine Mechanism of Action (MoA) with Improved Treatment Effect of Blarcamesine in Early Alzheimer Disease
Marwan N. Sabbagh 1, Juan Carlos Lopez-Talavera 2, Kun Jin 2, William Robert Chezem 2, Christopher U. Missling 2
1Barrow Neurological Institute - Phoenix (United States), 2Anavex Life Sciences - New York (United States)